Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Amplia Therapeutics (INNMF) Stock Price & Analysis

INNMF Stock Chart & Stats

$0.05$0.00(0.00%)
At close: 4:00 PM EDT
$0.05$0.075$0.13 Aug17 Aug31 Aug15 Sep28 Sep12 Oct28 Oct
Day’s Range
$0.05 - $0.05
52-Week Range
$0.05 - $0.27
Previous Close
$0.05
Volume
10.00K
Average Volume (3M)
16.37K
Market Cap
$30.31M
Enterprise Value
$93.06M
Total Cash (Recent Filing)
$27.85M
Total Debt (Recent Filing)
$341.11K
Price to Earnings (P/E)
―
Beta
-1.47
Next Earnings
Nov 25, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Equity Cushion And Low Leverage

Equity represents most of the asset base, while debt remains modest, giving Amplia a meaningful solvency cushion. This balance-sheet structure can provide greater flexibility to fund development and absorb operating volatility than a highly leveraged biotechnology company.

Historically Strong Gross Margins

Strong gross margins in periods when revenue was generated indicate that the underlying offering has previously supported attractive unit economics. If revenue is restored, this history could help the company retain more revenue for research, development, and other operating needs.

Defined Oncology Development Focus

A focused oncology program gives Amplia a clearly defined development direction rather than a broad, unfocused portfolio. Concentrating resources on narmafotinib and FAK biology may improve strategic coherence as clinical development progresses over the coming quarters.

Bears Say

Revenue Has Fallen To Zero

The collapse to zero revenue shows that Amplia currently lacks a dependable commercial or recurring revenue stream. That leaves the company reliant on financing or other sources of capital to support operations and clinical development, increasing execution pressure over the next several quarters.

Persistent And Widening Losses

Recurring losses indicate that the business is not yet covering its operating costs and has not demonstrated sustainable profitability. Widening losses can consume the balance-sheet cushion more quickly and may constrain the pace or scope of future clinical investment.

Worsening Cash Burn

Negative operating and free cash flow every year, combined with a larger operating outflow in 2026, shows that cash consumption remains a central funding risk. Continued burn reduces financial flexibility and makes disciplined capital allocation important while development programs advance.

Amplia Therapeutics News

INNMF FAQ

What was Amplia Therapeutics’s price range in the past 12 months?
Amplia Therapeutics lowest stock price was $0.05 and its highest was $0.27 in the past 12 months.
What is Amplia Therapeutics’s market cap?
Amplia Therapeutics’s market cap is $30.31M.
When is Amplia Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Amplia Therapeutics’s earnings last quarter?
Amplia Therapeutics released its earnings results on May 29, 2026. The company reported -$0.005 earnings per share for the quarter.
Is Amplia Therapeutics overvalued?
According to Wall Street analysts Amplia Therapeutics’s price is currently Undervalued.
Does Amplia Therapeutics pay dividends?
Amplia Therapeutics does not currently pay dividends.
What is Amplia Therapeutics’s EPS estimate?
Amplia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics have?
Amplia Therapeutics has 513,312,000 shares outstanding.
What happened to Amplia Therapeutics’s price movement after its last earnings report?
Amplia Therapeutics reported an EPS of -$0.005 in its last earnings report. Following the earnings report the stock price went down -3.061%.
Which hedge fund is a major shareholder of Amplia Therapeutics?
Currently, no hedge funds are holding shares in INNMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology